

Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia

NCT06769997

Status	RECRUITING
Phase	Not Applicable
Sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (3)

- Male subject with symptomatic BPH.
- Prostate size 30-100g.
- Able to complete the study protocol.

Exclusion (11)

- Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with follow-up requirements
- Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate
- Any prior minimally invasive intervention (e.g., TUNA, Balloon, Microwave, Rezkm, UroLift) or surgical intervention of the prostate
- Confirmed or suspected malignancy of prostate or bladder
- Active urinary tract infection (UTI) confirmed by culture
- ... and 6 more (see full listing online)

Locations (1 total)

Centre Hospitalier de l'université de Montréal (CHUM), Montreal, Quebec, Canada